Type 1 Diabetes: FDA Approves Tzield for Children Aged 8 to 17
The FDA grants accelerated approval to Tzield (teplizumab-mzwv) to slow down the degradation of endogenous insulin production in children aged 8 to 17 who have been recently diagnosed with stage 3 type 1 diabetes. This status marks a first for this therapeutic indication.
Targeted Approval for Stage 3 Pediatric Type 1 Diabetes
The FDA has approved Tzield for children aged 8 to 17 who have been recently diagnosed with stage 3 type 1 diabetes. This stage corresponds to when patients typically begin to exhibit common symptoms of the disease. The laboratory specifies that Tzield is not effective as a disease-modifying therapy for non-autoimmune dysglycemic conditions. According to Breakthrough T1D, about 64,000 people are diagnosed with type 1 diabetes each year. The approval provides a specific therapeutic option for certain patients diagnosed at stage 3.
Clinical Data from Over 900 Treated Patients
The approval is based on data from the phase 3 PROTECT study (clinical identifier: NCT03875729) as well as additional data from the global clinical development program involving more than 900 patients who received Tzield. In the PROTECT study, Tzield significantly slowed the decline of beta-cell function, assessed by the decrease in average C-peptide levels after a four-hour mixed meal tolerance test: the difference in least squares means was 0.13 pmol/mL, with a 95% confidence interval of 0.09 to 0.17 and a p-value less than 0.001.
